Medisix Therapeutics
Singapore
About Medisix Therapeutics
Medisix Therapeutics is a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Their technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Their programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $20.0M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2018)
- Website: medisixtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Chemical Engineering, Life Science
Social Profiles
Canonical: https://fsome.com/organization/medisix-therapeutics-163819 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.